HAEMATO AG – IFRS Results Q3 2017 (news with additional features)

DGAP-News: HAEMATO AG / Key word(s): Quarterly / Interim Statement/Quarter Results

30.11.2017 / 15:05

The issuer is solely responsible for the content of this announcement.


HAEMATO AG is a listed pharmaceutical company with focus on the growth markets of high-end specialty pharmaceuticals in the indication groups of oncology and HIV as well as in the areas of rheumatism, neurology and cardiovascular diseases. In addition, the in-house development of innovative medical devices for the beauty market has started. HAEMATO AG expects that first products will be launched in the coming year, which has already created the basis for further growth and additional income.

HAEMATO AG, Berlin (ISIN: DE0006190705), achieved IFRS consolidated sales of EUR 72.5 million and an operating result (EBIT) of EUR 2.45 million in the third quarter of 2017. Sales thus increased by 2.4% in the comparable prior-year period. Within the first nine months of 2017, total revenue amounts to 211.3 million euros and EBIT to 5.64 million euros. The Management Board forecasts consolidated revenue of more than 280 million euros for the entire 2017 financial year.

About HAEMATO:

HAEMATO AG, founded in 1993, is a pharmaceutical company. The emphasis of business activities lies on the growth markets of high-priced specialty pharmaceuticals. The focus lies on therapies for cancer, HIV and other chronic diseases.

HAEMATO AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange. Key figures for the share of HAEMATO AG:
Subscribed capital: EUR 21,980,000
Listed share class: bearer ordinary shares
ISIN: DE0006190705 * WKN: 619070 * Stock symbol: HAE

Contact:
HAEMATO AG, Investor Relations
Telefon: +49 (0)30 897 30 86 70
ir@haemato.de


Additional features:

Document: http://n.eqs.com/c/fncls.ssp?u=CXNTHHNWPT
Document title: HAEMATO AG – IFRS Results Q3 2017


30.11.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: HAEMATO AG
Lilienthalstraße 5c
12529 Schönefeld
Germany
Phone: +49 (0)30 897 30 86 70
Fax: +49 (0)30 897 30 86 79
E-mail: ir@haemato.de
Internet: www.haemato.de
ISIN: DE0006190705
WKN: 619070
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate Exchange

 
End of News DGAP News Service

show this